first described in 1905, with the demonstration of spirochetes in Giemsa-stained fluid from syphilitic lesions. 1 Person-to-person transmission can occur during sexual intercourse, congenitally, or rarely, through other means, including accidental direct inoculation by a blood transfusion. 2 Early in the 20th century, syphilis was a major public health problem. Transfusion-transmitted syphilis was first described in 1915. By 1941, 138 cases had been described in the literature? Serologic tests for syphilis (STS) have been performed on blood donations for more than 60 years, which is the longest of any infectious disease test. Transfusion-transmitted syphilis has become nonexistent in the United States because there have been no reported cases in more than 30 years. Yet, of all the tests performed on blood donors, least is known about the current rationale for this test and the significance of the test results in the blood-banking environment. There are 2 questions that we keep asking: (1) Are we detecting any truly infectious donors? and (2) If not, what is the significance of a confirmed positive test for syphilis in the contemporary allogeneic blood donor?
This review will summarize what is and what is not known about syphilis testing in blood donors and will suggest further work, the results of which may help answer these questions and thus the potential to change our testing practices or how we manage the counseling of blood donors who have positive STS.
WHAT WE KNOW

Natural Histo~ of Disease
In nature, syphilis is contracted during sexual intercourse by passage from genital lesions of 1 partner though the mucous membranes of the other partner. Intracutaneous inoculation results in the organism multiplying at the primary site 4 and presence of organisms in local lymph nodes within minutes and systemic dissemination within hours. 1,5 Within 4 days, the spirochetes disseminate by invasion of the local lymph nodes causing swelling (lymphadenopathy) followed by seeding to the bloodstream in large numbers. 4 Localized lymphadenopathy and primary lesions (chancres) develop in 9 to 90 days, with an average of 21 days. 6, 7 The primary chancre can be found in up to 97% of infected individuals, although up to 60% may not remember having had a lesion. Chance healing will occur spontaneously in about 2 to 6 weeks, although lymphadenopathy persists. 4,7 Progression from primary to secondary disease occurs in approximately 46 days (range 30 -70 days). 7
If untreated, the spirochete begins migrating to the bloodstream, and the disease progresses to the secondary phase 6 to 12 weeks after exposure (2 -8 weeks after development of the chancre), 5,7 with a corresponding vigorous antibody response. 5 Once the organism has invaded the bloodstream, it continues to infiltrate all organs and body fluidsY Peak spirochetemia with high organism load and systemic infection occur during secondary syphilis. A generalized condition with parenchymal, systemic, and mucocutaneous manifestations occurs. 7 Secondary phase is the most clinically apparent and is characterized by acute infection caused by multiplication and systemic dissemination of the organism. During secondary syphilis, spirochetes are cleared from the bloodstream, probably by a lytic process involving complement. Untreated secondary disease lasts a mean of 3.6 months, with a range of 1 to t2 months. 7 In 50% of cases, the patient will no longer be infectious or exhibit any symptomatology and will be considered cured. The other 50% will go on to a latent phase. 4 This stage progresses to the asymptomatic latent phase in which a positive serologic test for syphilis will be the only indicator of infection. 7
The latent stage of disease is characterized by complete asymptomatology with positive serology being the only evidence of infection. 7 During this time, the organisms remain dormant and are undetected in blood and tissues. There are no cutaneous manifestations or clinical symptoms, but the organism may be actively replicating in target organs. Although most patients in late latent syphilis remain asymptomatic, one third go on to tertiary syphilis 10 to 20 years later. 8 This latent stage may persist for life or progress several years or decades later to tertiary syphilis, which may result in gummatous lesions, cardiovascular, or neurologic disorders. 9 Approximately 30% of untreated patients progress, over a period of many years, to the tertiary stage with progressive disease occurring in the ascending aorta and central nervous system. 7
Antibody Development and Testing
In 1906, August von Wasserman ~ developed the first test for syphilis and so began serologic testing for syphilis. This test was a nontreponemal serum reagin test, the availability of which allowed for the testing of blood donors beginning in the 1940s. m Over the years, tests have been modified and changed, improvements made in specificity, and treponeme-specific antibody tests developed. More recently, treponemal-specific antibody tests have been automated. A summary of these tests is described in Table 1 .
Nontreponemal tests. Nontreponemal tests in
individuals with early primary syphilis may be negative in 30% to 50% of cases. Humoral antibodies are detected by these tests 1 week after development of the primary chancre, a 3 to 5 weeks after acquiring infection. 11 Nontreponemal tests are made with cardiolipin antigen designed to detect the IgM (also known as reagin) and IgG antibody produced in response to syphilis infection. These antibodies are directed at a lipid hapten antigen called cardiolipin, which can be found in many tissues as well as within the spirochete. The source of the cardiolipin that induces the nonspecific antibody development is unclear. Serologic screening tests have been developed to detect the antibody-cardiolipin complex by using complement fixation, precipitation, or flocculation. 12 Antibody titers decline after the secondary phase and may become undetectable in both treated (3 months -1 year) and untreated individuals. H,13
The rapid plasma reagin (RPR) is the most commonly used nontreponemal test for donor screening today. RPR uses a combination of cardiolipin antigen and charcoal and measures antilipin antibodies formed in the immune response. The resulting flocculation is a result of a suspended antigen antibody complex that is formed. This test result will revert to nonreactive over time after treatment but varies depending on the interval of time between contact and treatment and severity of illness. Persistence of these tests usually indicates persistent infection, reinfection, or a false-positive test result. 7 A second test that is specific for treponemes should be used for confirmation. ~2 In 1965, hemagglutination assay technology was applied for the development of treponeme-specific testing. The resulting Tpallidum hemagglutination assay (TPHA) was further modified to a microhemagglutination (MHA-TP) format. This test could be used qualitatively, quantitatively, and was simple to use. Recently, the MHA-TP technology has been automated (PKSMTP, Olympus, Irving Texas), eliminating the subjectivity associated with the manual test interpretation. TPHA tests have detectable reactivity approximately 4 weeks after exposure. Antibody titers increase dramatically during secondary syphilis. During latent syphilis, or after treatment, the titers decline and may become undetectable, 9 although even after successful treatment, most infected individuals test positive for life. Because nonpathogenic treponemes cannot be immunologically distinguished from T pallidum, the TPHA tests will also detect antibodies to these organisms. 7
Agreement between the TPHA and FTA-ABS tests vary from 87% to 93%, depending on the study population. It has been suggested that the MHA-TP test may not be appropriate for routine use as screening procedures because 1% of the general population will have false-positive results. 8 However, current use of the PKXMTP for syphilis testing is standard in the blood-banking environment because of the ease of automation.
Sensitivity of all STS varies with an increase seen as time from exposure increases. 15 There is conflict in literature reviews regarding the earliest positive results for syphilis testing when comparing nonspecific cardiolipin tests with the treponeme specific tests. However, studies specifically evaluating this issue suggest that treponeme-specific antibody detection occurs at approximately the same time as the nonspecific 6,8 and possibly slightly sooner (Table 1) . 9 '15 Other Research Tests Rabbit infectivity testing. The "gold standard" for syphilis infectivity is rabbit infectivity testing (RIT) because it is a direct measure of infectivity. It appears that RIT requires approximately 10 viable organisms per inoculum to transmit infection. 16 Intertesticular or interdermal inoculation causes formation of a localized tissue lesion that remains infective for life, may be transferred to another animal, and causes positive STS. Incubation may require up to 90 days and multiple animal passages. Because it is impractical and expensive, it is used only in research settings and as a sensitivity reference for PCR testing.* Western blot. Western immunoblot technology is used in the blood donor environment to perform confirmatory testing of retroviruses. Extension of this technology has led to the development of a test using whole-cell, Tpallidum antigen.
Detection of at least 3 or 4 major antigens having molecular masses of 15.5, 17, 44.5, and 47 Kd indicate a positive test. With clinically confirmed samples, the sensitivity of the assay is 93.8%, and the specificity is 100%. Agreement between the Western blot (WB) assay and the FTA-ABS is greater than 95%, with the WB having equal or greater sensitivity. The WB assay showed no false positive or equivocal reactivities for nonsyphilitic specimens from individuals with previously falsepositive test results, elevatated gamma globulin, or antinuclear antibody, but 1 false-positive test results in a normal blood donor. Unfortunately, the number of samples tested in each group was small (19, 10, and 15, respectively Polymerase chain reaction. Polymerase chain reaction (PCR) has been used extensively for viruses and currently is in use for the detection of hepatitis C virus and human immunodeficiency virus (HIV) in blood donors. The principle of PCR technology is the use of successive rounds of in vitro replication of nucleic acid sequences using primers complementary to specific targets. Millions of copies of the target gene are made, making it possible to detect minute quantities of a transmissible agent in the blood. Although this technology is being used with transfusion-transmitted viruses, little work has been done related to transfusion-transmitted bacteria (ie, Tpallidum). 1. DNA. The first description of PCR for testing of T pallidum DNA was in 1990. This technique amplified the TmpA and 4D genes, had a sensitivity to approximately 65 organisms per 0.5 mL, and a specificity of approximately 96%. 16 In 1991, the description of the use of the highly conserved gene for the T paIlidum 47 Kd immunogeneic membrane protein was first reported. 19 This target is commonly used in PCR technology because it is rarely found to cross-react with other commensal spirochetes. 8 Early studies using normal sera and cerebrospinal fluid from 9 adults with untreated syphilis reported a sensitivity of 100% in samples with at least 10 organisms, but inhibitory effects caused a lower sensitivity at lower organism concentrations. Specificity was 100% against other bacterial flora and human DNA. 19 ~ More recently, the 47 Kd target has been used in a multiplex test format that includes testing for T pallidum DNA PCR with known infected samples compared with dark-field microscopy with a reported sensitivity of 91% and specificity of 100%. Analysis of unrelated organisms and other commensal treponemes indicated no cross-reactivity. 8 When compared with individual confirmatory PCR assays, concordance was 100%. When comparing PCR with STS, the specificity discrepancy (PCR negative, STS positive) between the 2 tests was attributable to a possible sampling error or a lower specificity of the dark-field microscopy because of commensal organisms and/or serologic false positives. The sensitivity discrepancies (PCR positive, STS negative) were reported to potentially occur in patients with early syphilis when STS specificity may be as tow as 75%. 2o
One limitation of PCR testing for T pallidum is the inability to differentiate between the DNA of viable or dead organisms. . This means that a sample can be diluted over 100-fold more than for DNAbased PCR while still detecting organisms (provided there is at least 1 organism per sample). Sensitivity testing of 20 clinical isolates that had been infectious using RIT was 100%. No crossamplification was detected by using other species as templates (100% specificity). 22
Recent Historic Perspectives of STS for Blood Donation
In 1985, although the requirement for syphilis testing was dropped from the American Association of Blood Banks Standards, the Food and Drug Administration (FDA) failed to support this change. The FDA's position at that time was that STS be retained as a potential surrogate for highrisk behavior for HIV infection, rather than as evidence of syphilis, and syphilis screening continued to be a mandatory requirement? ~ In 1995, the National Institutes of Health convened a Consensus Development Conference, which included discussion of the extent to which tests for syphilis contributed to transfusion safety and whether their use as in current practice be continued or modified. The resulting recommendation was to continue syphilis screening of all blood donors until such time as more information was available regarding the effect of component storage conditions on T pallidum survival and molecular techniques could assess the absence of T pallidum in serologically positive donated blood, w In 1999, the FDA requested the submission of available data to again re-evaluate the need for continued syphilis testing of blood donors. After presentation of data at the September 2000 Blood Product Advisory Committee Meeting, the committee voted that the current scientific data were insufficient to warrant discontinuation of donor testing for antibodies to syphilis.
Syphilis Screening as a Surrogate Marker for HIV
Although donor deferral strategies and routine testing for HIV have excluded nearly all HIVpositive donations, the usefulness of STS as a surrogate marker for HIV infection in seronegative blood donors is still being debated. In 1995, the National Institutes of Health also addressed the rationale of continuing syphilis screening as a surrogate marker for other transfusion-transmitted infections and concluded that the low efficacy was not sufficient by itself to warrant the continued use of syphilis screening in blood donors. 1~
The most extensive evaluation of syphilis screening as a surrogate marker for HIV was published in 1997. The source population included 4,468,570 donations collected between 1992 and 1994 at 18 American Red Cross (ARC) sites. Of an estimated t3 HIV infectious window-period donations potentially donated during this time, 0.2 would have been removed because of a reactive STS alone at a cost of over $16 million. 24 With the incorporation of HIV p24 antigen testing in 1995 and the addition of nucleic acid testing for HIV in 1999, the residual risk of HIV infectious windowperiod donations has been reduced even further, making the value of STS as a surrogate marker negligible, if of any value at all.
Routine Blood Donor Testing for Syphilis
Over the years, blood centers have shifted from the use of the nontreponemal tests (ie, RPR) to treponemal tests (ie, PKTMTP hemagglutination) for donor screening. This has been primarily because of the ease of automation and the minimalization of technologist-dependent interpretation of test results. However, this has led also to detecting lifelong antibodies (versus antibodies suggesting current, recent, or persistent infection).
The current routine blood donor testing algorithm for syphilis includes the use of either a nontreponemal test (RPR) or an automated treponemat test (PKTMTP) as the screening test. If this test is reactive, it is confirmed by testing with an additional treponemal test, the FTA-ABS or an enzyme immunoassay. Sensitivity of the PKTMTP test varies by phase of disease but has clinical sensitivity (that is, tested in individuals with clinically diagnosed disease) of 93.9% and specificity of 95.6%. The FTA-ABS has a relative sensitivity (that is, compared with clinical samples tested by PKTMTP) of 99% and specificity of 93%. Blood centers that use the PK~MTP as a screening test may further test the donor using the RPR as a measure of recent exposure for the purposes of donor counseling.
It is important to point out that all of these tests have been developed for diagnostic use and not for use as screening tests. The use of diagnostic tests for screening low-risk populations results in a relative increase in false-positive test results, which leads to a low-positive predictive value (PPV or percent of individuals who test positive and are currently infected) of a positive test. By using Baye's theorem, 25 the PPV of the combined tests (PKTMTP and FTA-ABS) can be calculated using the following formula:
Today, by using the incidence of clinical syphilis in the United States (2.6/100,000) as an estimate of prevalence, the PPV for disease detection in the general population can be calculated as being < 0.1%. Because blood donors are a low-risk population (and current methodology also detects antibody from old, treated disease), the PPV for this group may be even lower.
To show the number of donors in the United States per year affected by positive STS results, data from the ARC may be used and extrapolated. Between July 1998 and October 1999, approximately 7.45 million donations were tested for syphilis. Of these, 16,907 (--13,525 per year) had a reactive syphilis screening test result, and 40% had a confirmed positive FTA-ABS (--5,400 per year). Of the confirmed positives, 27% were RPR reactive. Because the ARC draws approximately 50% of US blood donors, doubling of these figures would yield an estimate of nationwide figures.
Interpretation of Positive Syphilis Test Results in Blood Donors
It is unclear if our multiple testing algorithms are truly identifying any infectious donations. A cases series report of platelet concentrates and serum samples from blood donors with PKTMTP+, FTA-ABS + STS, tested for T pallidum DNA and RNA was presented at the September 2000 Blood Products Advisory Committee meeting in Bethesda, MD. These samples were tested using the DNA test that was Tpallidum pol A-gene specific, a DNA test that was a mnltiplex PCR using a T pallidum 47 Kd gene target and/or an RT-PCR test for RNA using Tpallidum 16S ribosomal RNA as a template for production of a complementary DNA target, as previously described: At least 100 samples (50 RPR+ and 50 RPR-) were tested by each method. All samples were negative for evidence of T pallidum DNA or RNA. The lack of demonstrable T pallidum DNA or RNA suggests that the probability that the blood of donors who have confirmed positive syphilis test results is infectious for syphilis is 0% to 3%. 26 These results are in contrast to recent data reported from the analysis of 2 syphilis outbreaks in the United States, which found that Tpallidum DNA could be detected in the blood of untreated, infected individuals during all phases of syphilis infection. 2v,28 By extension, it is unlikely that blood donors with confirmed positive syphilis tests are truly infected with syphilis.
To what can we attribute confirmed and unconfirmed positive syphilis test results in blood donors? There is ample literature addressing conditions associated with false-positive syphilis test results. 6,7,8,t2,29,3~ To determine if these conditions applied to blood donors, a history of conditions reported to be associated with false-positive syphilis tests (Table 2) , and/or a previous history of syphilis infection was assessed by a case-control study of donors with reactive (both confirmed and nonconfirmed) and nonreactive PKTMTP test results by using an anonymous mail survey. Among responding blood donors, approximately 50% of donors with FTA-ABS-positive test results reported a syphilis history. There was no difference in reported false-positive conditions for either FTA-ABS-positive or FTA-ABS-negative cases, compared with controls. These results suggest that (1) a large proportion of confirmed positive test results are a result of old, treated infection and (2) although historically conditions in the literature associated with false-positive test results have been used to explain both unconfirmed and confirmed 
Biological Properties Relevant to Potential Transfusion Transmission
The properties necessary to classify an infectious agent as potentially transfusion transmissible include presence in blood; infectious asymptomatic, carrier or latent stages; and stability or growth of the agent in stored blood or blood components, 33 such as red blood cells and platelet concentrates.
Several additional factors influence the probability of a blood donor being truly infected with syphilis and thus the probability of the presence of treponeme in blood. First, the frequency of syphilis infection in the general population has changed over time. In 1947, before the discovery and use of penicillin, the incidence of primary and secondary syphilis was 66.4 cases per 100,000 persons. ~ The last syphilis epidemic was in 1990 when the incidence was 20.3 per 100,000 persons. More recently, the incidence of syphilis has decreased as a widespread disease (2.6/100,000 in 1998). 34 This low incidence in the general population decreases the probability of a blood donor being infectious for syphilis. Second, properties of the different phases of syphilis infection may be related to the likelihood that an individual would present as a blood donor and/or that an individual's blood is infectious. Early primary syphilis is characterized by rapid dissemination that may precede antibody development and symptomotology and has resulted in documented transfusion acquired infection from blood donors in the seronegative window period. 8 Although this potential has always been present, we still have not seen a documented case of transfusion-tranmitted syphilis in the United States in over 30 years. Conversely, secondary phase is the most clinically apparent and is characterized by acute infection caused by multiplication and systemic dissemination of the organism, with peak spirochetemia. 8 It is unlikely that an infected individual in this phase would present as a blood donor. Finally, untreated syphilis can progress to a latent phase. Although there is data regarding T pallidum DNA detection, the infectious potential for blood in this phase is not well described.
Inoculation studies have shown that the infectious potential of whole blood stored at 4~ is directly proportional to the size of the inoculum.
Inoculum concentrations of 5.0 • 10e4 treponemes/mL, 1.25 • 10e6 treponemes/mL, and 2.5 • 10e7 treponemes/mL were able to induce syphilis in rabbits up to 36 hours, 72 hours, and 108 hours, respectivelyY ,36 Because current transfusion demands for red blood cells often lead to the transfusion of blood that is a few days old, it cannot be assumed that storage at 4~ would preclude transfusion transmission of the agent.~~ WHAT WE DO NOT KNOW Several hypotheses have been put forward to explain the lack of reports of transfusion-transmitted syphilis. These include (1) a low incidence rate of the disease, (2) movement to all volunteer blood donors, (3) deferral of individuals with high-risk behaviour using donor history questionnaires, (4) serologic testing of blood donors, (5) the impact of refrigeration on the survival of the spirochete, (6) use of antibiotics in hospitalized patients, and (7) transmission with an as yet undetected infection30
Preparation and storage of individual blood components may have an impact on the potential for transfusion transmission. However, several key factors that could affect this potential are unknown. First, the concentration of treponeme in the blood of a naturally infected individual at different phases of infection has not been published. Preliminary data on 5 blood samples from individual's studied in a syphilis outbreak in Maricopa County, AZ, suggest that the concentration of treponeme varies from approximately 50 to 100,000 organisms per mL, depending on the phase of infection. 27 Second, the early 4~ storage studies make no comparison to any other storage temperature. Therefore, no reliable information is available on the true effect 4~ storage has on T pallidum survival. Conversely, platelet concentrates are stored in bags designed to facilitate oxygen flow. This property of the platelet bag leads to an internal oxygen content (--15%) higher than that which can be withstood by the Tpallidum spirochete (1% -4%), 37 although the actual impact on survival time is unknown.
Evidence that the Tpallidum spirochete attaches to the surface membrane of phagocytes 38 may have implications for the increased use of leukoreduction filters. Transfusion medicine is moving toward a policy of universal leukoreduction of all cellular blood components (ie, red blood cells and platelets) for the removal of white blood cells. This universal leukoreduction may impact the potential for transfusion-transmitted syphilis.
It is unlikely that a transfusion-transmitted case of syphilis would not be identified, based on past descriptions of transfusion-transmitted syphilis, which presented as acute, fulminant symptomatic secondary syphilis. 39 In addition, very specific antibiotic use would have to occur to cure a patient with transfusion-transmitted syphilis. The acute symptomatology usually associated with the spirochetemic phase of the disease may also make it unlikely that an infected individual would present as a blood donor. However, none of the hypotheses stated earlier have been fully tested.
Testing Limitations
A serious limitation of many published articles is the lack of a gold standard for diagnosis of syphilis in blood donors. The gold standard for syphilis testing, RIT, is not used routinely in the evaluation of licensed test kits for diagnosis and/or screening of blood donors. For the purposes of overall sensitivity determination, clinical diagnosis has been used as the gold standard. As new tests are developed, sensitivity and specificity testing are calculated and compared relative with the standard test in use at that time, rather than by testing large groups of samples from clinically diagnosed individuals. This type of comparison may be useful in comparing positive tests (ie, reactivity or titers) in individuals with independent assessment of disease but can be misleading when used with both negative and positive tests in populations without a gold standard disease classification. The resulting relative sensitivity and specificity values reported by the manufacturer may result in a high PPV in diagnosing populations likely to be infected but has questionable applicability when used for screening in low-risk populations, such as blood donors, and may result in disease misclassification.
It should also be noted that although reactive STS are confirmed with an additional test, the use of a multiple test algorithm with tests that lack independence of test results (have commonality of false positives or detection of old antibody) means that the additional test results may not provide additional diagnostic information. 15 An assumption of increased specificity of a con~firmatory test calcu]ated using the results found when screenreactive individuals are tested is misleading. This perceived increase in specificity is a result of a greater probability of disease after a second positive test result and reflects the increased prevalence in the population tested. As an example, for the FTA-ABS test, studies of unselected sera run in parallel do not support the increased specificity reported in the literature. 15 In individuals who have no evidence of syphilis, even multiple positive tests are not a substitute for clinical judgment. 39 
Information for Blood Donors
The relevance of a confirmed positive syphilis test result in an apparently healthy blood donor is an issue today. Although there is ample literature addressing false-positive test results associated with specific conditions when using the current methodology, these conditions may not be relevant to the contemporary interpretation of positive STS in blood donors.
For 
